Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

NCT05941442 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05941442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05941442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2023
Completion date
March 31, 2025
Enrollment
80 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

panic disorder